Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keramod versus Aldara for actinic keratosis
2019-002285-12Phase 2Active
- Sponsor
- Ojer Pharma
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Keramod in actinic keratosis (AK) (2 arms), sponsored by Ojer Pharma. Primary endpoint: Complete clearance of actinic keratosis lesions. Started Oct 2019; status: active.
02
Drugs
Keramod
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on 2019-002285-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002285-12.